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Novel glomerular lipoprotein deposits associated with apolipo- ized by unique histologic findings, such as lipoprotein
protein E2 homozygosity. thrombi in dilated glomerular capillaries. Patients with
Background. Hyperlipoproteinemia is occasionally associ- LPG exhibit type III hyperlipoproteinemia or dysbetali-ated with severe glomerular injury caused by abnormal accu-
poproteinemia, progressive renal dysfunction, protein-mulation of lipid in glomeruli, which occurs in conditions such
as lipoprotein glomerulopathy (LPG). This study investigates uria, and in some cases, nephrotic syndrome [2–7]. Re-
the cases of two siblings with homozygous apolipoprotein (apo) cently, it has been reported that new apolipoprotein
E2 who show unique histologic features, massive proteinuria, (apo) E variants, apo E Sendai (145Arg!Pro) [8], apo Eand dysbetalipoproteinemia.
Kyoto (25Arg!Cys) [9], and 18 amino acid (residues 156Methods. Histologic studies were performed using renal
to 173, apo E1) [10] or 3 amino acid (residues 141 tobiopsy specimens. Plasma lipoproteins were extensively charac-
terized. The exons of the apo E genes were sequenced to avoid 143, apo E Tokyo) [11] deletions of apo E are associated
missing any mutations. with LPG. The impaired metabolism of lipoproteins
Results. Histologically, the siblings’ condition resembled LPG
caused by these apo E variants or the apo E variantsby light microscopy studies. Electron microscopy studies re-
per se are thought to play a pathogenic role in the devel-vealed large lipoid deposits in the paramesangium, subendo-
thelium, and subepithelium of the glomeruli, which were differ- opment of this disease.
ent from LPG in terms of not forming the layered structure On the other hand, it is well known that apo E2 (158Arg!
resembling a fingerprint even in large lipoprotein thrombi, Cys) has a low-density lipoprotein (LDL) receptor bind-and mesangial foam cells. Immunohistochemically, the lipoid
ing affinity of only 2% of that of wild-type apo E3 [12, 13],deposits contained apo E and apo B. These patients did not
have either diabetic nephropathy or other known forms of and homozygosity for apo E2 is the most frequent pre-
glomerulonephritis. The sequence of exons of the apo E genes requisite for the development of type III hyperlipopro-
revealed homozygosity for apo E2 in both cases. teinemia [13, 14]. The apo E2 allele may be a genetic
Conclusion. The extensive lipoprotein deposition in glomer-
predisposition to the development and progression ofuli, which resembles LPG, can also occur in apo E2 homozygous
renal diseases [15–18], and when severe type III hyperli-individuals, but in a distinct fashion. Because the two cases
were siblings, they may have other shared alleles, in addition poproteinemia is overt, apo E2 homozygosity occasion-
to the apo E2 allele, that negatively affect processing of lipopro- ally elicits progressive glomerular damage accompanied
teins and lead to abnormal accumulation of lipoprotein deposits
by abnormal accumulation of foam cells [19–22]. How-in glomeruli.
ever, apo E2 homozygosity has not been reported to be
associated with LPG even though the frequency of apo
E2 homozygosity, 0.5% in the Japanese population [23],Hyperlipoproteinemia is occasionally associated with
may be much higher than that of the apo E variants thatglomerular injury because of abnormal accumulation of
are associated with LPG.lipid in glomeruli [1]. Lipoprotein glomerulopathy (LPG)
Lipoprotein glomerulopathy seldom presents with mas-has been recognized as one such disease. It is character-
sive foam cells in glomeruli, even though it is accompa-
nied by type III hyperlipoproteinemia or dysbetalipopro-Key words: proteinuria, heredity, dysbetalipoproteinemia, type III
hyperlipoproteinemia, glomerular foam cells, thrombi. teinemia [2, 3, 7]. The renal damage caused by severe
type III hyperlipoproteinemia due to apo E2 homozygos-
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ity rarely includes lipoprotein thrombi. Therefore, theseand in revised form October 26, 2000
Accepted for publication November 20, 2000 two glomerulopathies are thought to be distinct from
each other. This study examines two siblings with homo-Ó 2001 by the International Society of Nephrology
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Table 1. Lipid studies (1)zygous apo E2 who showed both extensive lipoprotein
deposits, including lipoprotein thrombi and glomerular Brother Sister
foam cells. TC (129–219) mg/dL 177 345
TG (32–220) mg/dL 159 395
PL (156–255) mg/dL 223 314Patients
Apolipoproteins
The cases were siblings and had no other siblings. The A1 (122–161) mg/dL 144 113
A2 (25.1–34.5) mg/dL 22 27parents of the cases are deceased. Their mother had
B (69–105) mg/dL 78 156hyperlipidemia, but no further information was avail-
C2 (1.6–4.2) mg/dL 6.9 15.1
able. It was uncertain whether she had renal disease or C3 (5.5–9.5) mg/dL 19.9 26.0
E (2.7–4.5) mg/dL 9.2 24.1even proteinuria. Each patient had three children who
Lipoprotein lipase (136–321) ng/mL 148 227were from 19 to 25 years of age and who had not pre-
Lecithin-cholesterol (235–550,a
sented with persistent proteinuria, according to the urine Acyl transferase (LCAT) 53–108b) U/L 350a 182b
dipstick test. There were no other family members who Normal ranges are in parentheses. Abbreviations are in the Appendix.
The activity of LCAT was measured by either a the liposome substrate methodsuffered or had suffered renal diseases or hyperlipid-
or b the dipalmitoyl lecithin substrate method.emia. The marriages of the parents or grandparents of
these patients were not consanguineous.
Brother. A 52-year-old Japanese man was admitted
Sister. A 49-year-old Japanese woman was admitted
to Niigata University Hospital on June 8, 1998, because
to Niigata University Hospital on September 25, 1998,
of general fatigue and pretibial edema. He had been
because her family physician had detected hypertensionobserved to have proteinuria on an annual medical ex-
(BP 182/90 mm Hg), hyperlipoproteinemia, and protein-amination since 1990. Under the clinical diagnosis of
uria. Two months before admission, antihypertensiveschronic glomerulonephritis, a renal biopsy had been per-
and diuretics had been prescribed. On admission, a phys-formed in 1990, and he had been diagnosed as having
ical examination showed no abnormalities except foran unclassified type of glomerulopathy showing mesangi-
slight pretibial edema. Her body weight and height wereolysis and a double contour of the capillary wall of the
62.2 kg (BMI 25.2) and 157.2 cm, respectively. She didglomeruli without deposits of immunoglobulins. Urinary
not show cutaneous xanthomas, thickening of the Achil-protein excretion had increased gradually (up to 3 g/day),
les tendons, or any signs of arterial stenosis. Fundoscopicand treatment with low-dose aspirin and prednisolone
examination of eyes showed no sclerotic or diabetichad been started. On admission, his body weight, height,
changes in arterioles. The echocardiogram was normal.and blood pressure (BP) were 62.0 kg [body mass index
Urinalysis revealed proteinuria (4.0 g/day), but no hema-(BMI), 20.7], 173.1 cm, and 126/78 mm Hg, respectively.
turia. Renal function was normal (BUN 8 mg/dL, SCrPhysical examination showed no abnormalities other
0.5 mg/dL, and CCr 147 mL/min). Hyperlipoproteinemiathan mild pretibial edema. He had neither cutaneous
was detected (Table 1). Other laboratory findingsxanthomas nor thickening of the Achilles tendons and
showed only mild liver dysfunction consistent with fattyshowed no signs of arterial stenosis, such as vascular
liver, which was revealed by abdominal ultrasonographybruit or laterality of pulsation of pedal or radial arteries.
examination. An oral glucose tolerance test indicatedNo abnormalities such as arteriolosclerosis or diabetic
that she had normal glucose tolerance. IgG and IgAretinal changes were found on fundoscopic examination
levels were lower than normal limits, and the IgM levelof eyes. The echocardiogram was normal. Urinalysis re-
was normal. The levels of complement system compo-vealed proteinuria (2.5 g/day), but no hematuria even
nents and electrolytes were within the normal range.on microscopic examination. Hyperlipoproteinemia was
Antinuclear antibody and paraprotein were not detectednot detected (Table 1). Other laboratory findings include
in the serum.the following: blood urea nitrogen (BUN) 15 mg/dL,
serum creatinine (SCr) 0.8 mg/dL, creatinine clearance
(CCr) 117 mL/min, serum total protein (TP) 5.0 g/dL, and METHODS
albumin 3.3 g/dL. The concentration of serum electro-
Renal biopsy and histologic studylytes, including sodium, potassium, chloride, calcium,
Percutaneous renal biopsies were performed after ad-and phosphorus, were within the normal range. Circulat-
mission to Niigata University Hospital. Informed con-ing blood cell counts were normal. An oral glucose toler-
sent was given by both patients. For light microscopyance test indicated that he had normal glucose tolerance.
studies, tissues were fixed with alcohol-bouin, embeddedThe level of serum IgG was lower than normal limits,
in paraffin, and treated with periodic acid-Schiff (PAS),and IgA and IgM levels were normal. The levels of com-
periodic acid methenamine silver (PAM), and Masson’splement system components were within the normal
trichrome stain. For immunohistochemical studies, tis-range. Serum was negative for antinuclear antibody and
paraprotein. sues were snap frozen, and sections were treated with
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fluorescein isothiocyanate (FITC)-conjugated rabbit anti-
human immunoglobulin (Ig)G, IgA, IgM, C1q, C3c, or
fibrinogen (Dako, Carpinteria, CA, USA). For apolipo-
protein detection, goat anti-human apo B or apo E anti-
bodies (Chemicon International Inc., Temecula, CA,
USA) were used as primary antibodies, and the sections
were then treated with FITC-conjugated anti-goat Ig
antibody (Tago, Camarillo, CA, USA). The frozen sec-
tions were also stained by oil-red O to detect lipid in
the tissue. For electron microscopy studies, samples were
fixed with 2.5% glutaraldehyde and 2% paraformalde-
hyde and were postfixed with 1% osmium tetroxide.
After being embedded in Epon 812, samples were double
stained with tannic acid and lead.
Fig. 1. Light microscopy studies. A number of pale-stained deposits
are accumulated in an enlarged glomerulus (PAS stain, 3100).Lipoprotein study
After a 12-hour fast, blood samples were collected into
tubes containing 0.1% ethylenediaminetetraacetic acid
(EDTA), and plasma was separated by centrifugation AGGAT-39 (primer 2)], for the first half of exon 4 [sense,
(2000 g 3 15 min). Very LDL (VLDL), intermediate- 59-TGCGACACCCTCCCGCCCTCT-39 (primer 3); anti-
density lipoprotein (IDL), LDL, and high-density lipo- sense, 59-CACGCGGCCCTGTTCCACCAG-39 (primer
protein (HDL) were isolated from plasma by sequential 4)], and for the second half of exon 4 [sense, 59-GCCT
ultracentrifugation as described elsewhere [24, 25]. Val- CAGCGCCATCCGCGAGC-39 (primer 5); antisense,
ues of total cholesterol (TC), triglyceride (TG), and phos- 59-CATGGCTGCAGGCTTCGGCGT-39 (primer 6)].
pholipid (PL) were determined enzymatically. Plasma The design of these primers was based on the genomic
concentrations of apolipoproteins were measured by tur- sequence of the apo E gene published previously [31].
bidity immunoassay (TIA). The activity of lecithin-cho- Because each PCR product gave a single band when
lesterol acyltransferase (L-CAT) was measured by either
electrophoresed on a 2% agarose gel, amplified DNA
the liposome substrate method [26] or the dipalmitoyl
was purified from whole PCR mixture using a centrifugelecithin substrate method [27]. The concentration of lipo-
tube with a filter membrane (Suprec-02e; Takara, Shiga,protein lipase (LPL) was measured by enzyme-linked
Japan). Then the purified PCR products were directlyimmunosorbent assay [28] using MARKIT-FLPL (Dai-
sequenced with the same PCR primers as described pre-nippon Pharmaceutical, Co. Ltd., Osaka, Japan). Plasma
viously in this article, using a cycle sequencing kit (Big-for the measurement of LPL activity was collected after
Dye Terminator Cycle Sequencing Kite; Perkin-Elmer,the intravenous administration of heparin (30 U/kg). To
Applied Biosystems, CA, USA) and the ABI-PRISMinvestigate the lipoprotein profiles on polyacrylamide
model 310e (Perkin-Elmer, Applied Biosystems). Se-disc gels, sera from a healthy volunteer and the patients
quencing was performed bidirectionally with the 59-sensewere prestained with 0.1% Sudan Black B and then
and 39-antisense primers.electrophoresed on a 3% polyacrylamide disc gel as de-
scribed previously [29]. The lipoprotein bands were
scanned at 610 nm by a photodensitometer. RESULTS
Renal histologyPhenotyping, genotyping, and sequencing of apo E
Light microscopy. Six glomeruli were evaluated in theApolipoprotein E phenotyping was performed by an
brother’s biopsy specimen. No glomeruli showed globalisoelectric focusing method using a phenotyping apo E
sclerosis. In the sister’s biopsy specimen, a total of 27kit (Joukou, Tokyo, Japan). Genotyping of genomic
glomeruli was evaluated, six of which showed globalapo E genes was performed using the “one-stage poly-
sclerosis. In both cases, by PAS stain, most glomerulimerase chain reaction (PCR) method” as previously re-
showed hypertrophy and dilated capillaries. A numberported [30]. The PCR products were digested with Hha I,
of pale-stained deposits were observed within the glo-and restriction fragment length polymorphisms (RFLPs)
meruli, and mesangial areas looked mesangiolytic. By awere determined after electrophoresis on a 20% poly-
PAM stain, the capillary walls showed segmental dupli-acrylamide gel. To sequence the apo E gene, genomic
cation and irregular spike formation. These were ob-DNA was amplified by PCR with following primers: for
served in all glomeruli of both cases. Foam cells wereexon 3 [sense, 59-CCCTGACCCACCTTGAACTTG-39
(primer 1); antisense, 59-AGGAGGGTCAAGGGCC observed in the interstitium in both cases, and this was
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Fig. 2. Electron microscopy studies. Numerous subendothelial, subepi-
thelial (arrows), and paramesangial lipid deposits are observed (A) in
both patients. Lamellar formation is not observed even in large deposits
or “lipoprotein thrombi” (arrow; C ). Mesangial foam cells (arrows) are
marked in the sister’s biopsy specimen (E). Deposits consist of fine
lipid particles in high power magnification (B and D). (The brother, A
32,500, B 315,000; the sister, C 33,500, D 310,000, E 33500).
especially marked in the sister’s biopsy specimen. Mild not as remarkable. The renal biopsy specimen of the
brother stained by PAS is shown in Figure 1.interstitial fibrosis and mild arteriolosclerotic changes
were also observed. The presence of oil particles in the Electron microscopy. In both cases, there were vari-
ous sizes of electron-dense deposits in the paramesan-glomeruli was demonstrated by oil-red O staining (data
not shown). The first renal biopsy specimen of the gium, subendothelium, subepithelium, and glomerular
basement membrane (Fig. 2A). Some looked like “lipo-brother, which had been taken in 1990, was re-examined,
and it showed essentially the same findings as the second, protein thrombi” occupying glomerular capillary lumina.
Even in large deposits, however, they did not form aalthough the alterations of glomerular structure were
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Table 1. Lipid studies (1)
Brother Sister
TC (129–219) mg/dL 177 345
TG (32–220) mg/dL 159 395
PL (156–255) mg/dL 223 314
Apolipoproteins
A1 (122–161) mg/dL 144 113
A2 (25.1–34.5) mg/dL 22 27
B (69–105) mg/dL 78 156
C2 (1.6–4.2) mg/dL 6.9 15.1
C3 (5.5–9.5) mg/dL 19.9 26.0
E (2.7–4.5) mg/dL 9.2 24.1
Lipoprotein lipase (136–321) ng/mL 148 227
Lecithin-cholesterol (235–550,a
Acyl transferase (LCAT) 53–108b) U/L 350a 182b
Normal ranges are in parentheses. Abbreviations are in the Appendix.
The activity of LCAT was measured by either a the liposome substrate method
or b the dipalmitoyl lecithin substrate method.Fig. 3. Immunohistochemical study. Indirect immunohistochemical
staining was performed with anti-apo E (the brother, A; the sister, C )
or anti-apo B (the brother, B; the sister, D) antibodies. Apo E and apo
B are stained in a granular manner, shaped like raindrops in some parts both cases, and apo B in the sister, were elevated. The
along glomerular capillary walls and mesangial areas (3400).
fractions of VLDL and IDL separated by sequential
ultracentrifugation were rich in cholesterol in both cases
and rich in TG in the sister, when compared with normal
controls that we had previously studied (described asstriated or layered structure resembling a fingerprint,
normal ranges in Tables 1 and 2) [24]. The VLDL-which is characteristic of LPG (Fig. 2C) [2, 7]. The depos-
cholesterol/TG ratio, which is the diagnostic index ofits consisted of homogeneous fine lipid particles (Fig. 2B,
type III hyperlipoproteinemia when it is over 0.25 or 0.3D). Matrix components were mildly increased in the
[14], was 0.16 for the brother and 0.42 for the sister.mesangial area. In spite of massive proteinuria, foot pro-
The lipoprotein profiles, generated by electrophoresiscesses were only partially fused. Foam cells were found
on polyacrylamide disc gels, showed broad, floating bin part of the mesangial area, and they were especially
bands (or b-VLDL; Fig. 4), which are characteristic ofnoticeable in the sister’s biopsy specimen (Fig. 2E).
dysbetalipoproteinemia [13, 14]. The activity of LCAT,Immunofluorescence. In both specimens, no immuno-
in which the deficiency is known to cause renal lipidosis,globulins were detected in the glomeruli. Positive stain-
was high in the sister and normal in the brother. LPLing for C3c and fibrinogen was observed along arterioles
was detected at normal levels in both cases. Apo E phe-and glomerular capillary walls, respectively. Because apo E
notypes, as determined by isoelectric focusing, and geno-and apo B are detected in the “lipoprotein thrombi” of
types, as determined by PCR-RFLP (one-stage PCRLPG [3], we attempted to detect apo E and apo B in
method [30]), were apo E2/2 in both patients (data notthe renal biopsy specimens. Strong, granular staining for
shown).apo E (Fig. 3A, C) and apo B (Fig. 3B, D) was observed
in the mesangial area and along the capillary walls, look-
Apo E sequencinging like big raindrops in some parts. There was also
positive apo E and apo B staining in the interstitium and Because apo E phenotyping by isoelectric focusing
along the vessel walls. As a negative control, the biopsy cannot distinguish unusual variants in which amino acid
specimen from an IgA nephropathy patient in the ab- substitutions are electrophoretically silent and because
sence of hyperlipidemia were simultaneously examined, PCR genotyping by the one-stage PCR method [30] can
and they were weakly positive for apo E and apo B when only distinguish the apo E2, apo E3, or apo E4 alleles,
compared with those of the two cases (data not shown). PCR-direct sequencing of the genomic apo E genes from
While these histologic observations had partial simi- the two patients were carried out, as described in the
larities to the pathological changes of LPG, they were Methods section. Sequencing of exons 3 and 4, which
different in terms of the fashion in which lipid deposits encode apo E proteins, revealed that both patients were
were formed (Fig. 3A, B, brother, and Fig. 3C, D, sister). homozygous for apo E2. Portions of the sequence, which
distinguish various apo E variants, are shown in Figure 5.
Lipoprotein study Because each PCR product amplified by specific primers
gave a single band when electrophoresed on an agaroseLipid and lipoprotein values in plasma are shown in
Tables 1 and 2. The brother did not exhibit hyperlipid- gel, the possibility of nucleotide deletions in exons such
as apo E1 (18 amino acid, residues 156 to 173) [10] andemia, whereas the sister had severe hyperlipidemia.
Plasma concentrations of apo E, apo C2, and apo C3 in apo E Tokyo (3 amino acid, residues 141 to 143) [11]
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Table 2. Lipid studies (2)
Cholesterol mg/dL Triglyceride mg/dL
VLDL IDL LDL HDL VLDL IDL LDL HDL
Brother 25.3 23.0 55.4 65.0 75.1 14.5 18.6 33.3
Sister 167.5 42.5 72.5 50.3 299.8 16.0 29.0 29.8
Normal range (5.1–19.5) (2.2–6.1) (88.4–138.8) (30.7–57.3) (23.1–78.3) (5.0–8.9) (14.8–29.6) (6.1–19.5)
Normal ranges are according to [24]. Abbreviations are in the Appendix.
Fig. 4. Lipoprotein profiles from polyacryl-
amide disc gel electrophoresis. The profiles
generated by scanning the lipoprotein bands
show broad, floating b bands (or b-VLDL),
which are characteristic of type III hyperlipo-
proteinemia or dysbetalipoproteinemia. The
dotted lines represent normal control.
was highly unlikely. There were no nucleotide peaks the variation of apo E molecules. LPG has been reported
to be associated with various types of apo E variants,lying on other nucleotide peaks over the whole sequence,
such as apo E2 Sendai [8], apo E2 Kyoto [9], apo Eindicating that the apo E alleles were homozygous.
deletion mutants [10, 11], and apo E2/5 variants [33].
However, LPG does not always develop in subjects with
DISCUSSION these apo E variants [10, 34]. Likewise, the type of glom-
The two sibling cases reported here showed a novel erulopathy reported in this study does not always occur
type of lipoprotein deposition in glomeruli, which is asso- in apo E2 homozygosity. Therefore, patients with abnor-
ciated with dysbetalipoproteinemia caused by apo E2 mal glomerular lipoprotein accumulation, including LPG
homozygosity. The features of renal histology are the and the glomerulopathy reported here, possibly have ad-
existence of extensive lipoprotein deposits in the para- ditional common abnormalities in metabolic processing
mesangium, subendothelium, and subepithelium, which of lipoproteins, as well as dysbetalipoproteinemia, which
look like “lipoprotein thrombi” in some places, and the could lead to glomerular lipoprotein deposition. As one
appearance of foam cells in the mesangium and intersti- candidate, the dysfunction of receptors for apo E, such as
tium. The lamellar formation of lipid deposits resembling LDL receptor-related protein (LRP), might be another
a fingerprint, which is characteristic of LPG [2, 7, 32], is factor for the induction of these diseases. However, the
absent. This indicates that abnormal lipoprotein deposi- systematic investigation of apo E metabolism may be
tion in glomeruli, including lipoprotein thrombi, can also necessary to understand the mechanism.
occur in individuals with apo E2 homozygosity, but in a Some reports indicate that the apo E2 allele is a possi-
distinct fashion. There is a report of a case with type III ble predisposing factor for the development or progres-
hyperlipoproteinemia due to apo E2 homozygosity in sion of renal damage, such as diabetic nephropathy
the review article [32], presenting with glomerular lipo- [15, 16] and IgA nephropathy [18]. It has also been re-
protein thrombi that are similar to those observed in ported that the frequency of the apo E2 allele is higher in
LPG. This is more evidence for the development of lipo- end-stage renal disease (ESRD) [17]. Ultimately, apo E2
protein thrombi even in individuals with the apo E2/2 homozygosity, when accompanied by severe type III
genotype. The difference between the histology of the hyperlipoproteinemia, sometimes causes glomerular lipi-
siblings and that of patients with LPG may be derived dosis and injury, which are characterized by a massive
cluster of foam cells in the glomeruli [19–22]. This featurefrom differences in lipoprotein metabolism caused by
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Fig. 5. Genomic DNA sequence of apo E
genes. The exons of apo E genes from the two
patients were fully sequenced as described in
the Methods section. Portions of the sequence
from the brother coding for 3Glu, 25Arg, 112Cys,
145Arg, 158Cys, 244Glu, and 245Glu, in which the
mutations distinguish apo E isoforms, such as
apo E2 (158Arg!Cys), apo E3 (wild type), apo
E4 (112Cys!Arg), apo E5 (3Glu!lys), apo
E7 (244Glu!lys, 245Glu!lys), apo E2 Sendai
(145Arg!Pro), and apo E2 Kyoto (25Arg!Cys)
are shown. Each PCR product amplified by
specific primers gave a single band, indicating
that deletions of amino acid, including resi-
dues 156 to 173 (apo E1) or residues 141 to
143 (apo E Tokyo), were highly unlikely.
There was no overlap of nucleotide peaks over
the whole sequence, supporting the conclusion
that the apo E alleles were homozygous. The
top figure represents the PCR and sequencing
primers 1 to 6, as described in the Methods
section, and also indicates the locations of nu-
cleotides coding for marked amino acid.
is partly coincident with our cases with regard to the the brother has been followed for 10 years since the
onset of this disease. Prednisolone was tapered off afterappearance of glomerular foam cells. However, those
reported cases with apo E2 homozygosity, except for the second renal biopsy. His renal function remained
normal, but proteinuria continued (3.0 to 7.5 g/day). Theone in a review article [32], did not show lipoprotein
thrombi. Moreover, the condition was reported to be sister has been followed for two years, and her renal
function also remained normal. Her severe hyperlipid-improved by lipid-lowering therapy [20, 22]. Both cases
reported in the current study mainly showed the various emia has been normalized by dietary control and admin-
istration of bezafibrate (400 mg/day), but proteinuria wastypes of glomerular lipoprotein deposits such as lipopro-
tein thrombi, and hyperlipidemia was absent in the still overt (2.0 to 4.0 g/day). Thus, renal function seems
to remain normal for years in this disease.brother. Thus, the renal injury of the two sibling cases
seems to be partly related to, but distinct from the condi- In conclusion, the cases of two siblings with dysbetali-
poproteinemia, who showed glomerular foam cells andtion, which is accompanied by massive foam cells in
association with severe type III hyperlipoproteinemia extensive lipoprotein deposits without a layered struc-
ture, are reported. The condition was unique from LPG.caused by apo E2 homozygosity.
Lipoprotein glomerulopathy has been characterized The studies of the apo E molecules, including genomic
DNA sequencing, confirmed that the siblings were bothby relatively rapid progression to renal impairment and
development of glomerulosclerosis [4, 34]. In our cases, homozygous for apo E2. The prognosis of renal function
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3-amino acid deletion mutation of apolipoprotein E (apo E Tokyo)seems to be relatively good, although massive protein-
with lipoprotein glomerulopathy. Nephron 83:214–218, 1999
uria continues. As well as dysbetalipoproteinemia, there 12. Weisgraber KH, Innerarity TL, Mahley RW: Abnormal lipopro-
tein receptor-binding activity of the human E apoprotein due tomight be another shared, probably genetic, abnormality
cysteine-arginine interchange at a single site. J Biol Chem 257:2518–in metabolic processing of lipoproteins in these sibling
2521, 1982
patients. Further investigation of these siblings and their 13. Mahley RW, Rall SC Jr: Type III Hyperlipoproteinemia (Dysbe-
talipoproteinemia): The Role of Apolipoprotein E in Normal andfamilies are now in progress.
Abnormal Lipoprotein Metabolism: The Metabolic Basis of Inher-
ited Disease (6th ed). New York, McGraw-Hill, 1989, pp 1195–1213
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